Contemporary Strategies for Managing and Controlling Viral Outbreaks: An Overview
Contemporary Strategies for Managing and Controlling Viral Outbreaks
DOI:
https://doi.org/10.53560/PPASB(61-sp1)1004Keywords:
Blood-borne viruses, Epidemic, Pandemic, Respiratory viruses, Vector-borne viruses, Viral outbreaksAbstract
Viruses are notorious for causing a significant array of infectious diseases, rendering them a prominent contributor to global morbidity and mortality rates. Throughout history, various regions have experienced outbreaks, epidemics, and pandemics, resulting in significant mortality rates. The Influenza virus gave rise to highly fatal outbreaks that disseminated on a global scale, subsequently resulting in a pandemic during the initial decades of the 20th century. This catastrophic event led to >75 million fatalities, accompanied by a substantial incidence of illnesses. In addition to the development of efficacious treatments for viral diseases, it is imperative to establish and implement various preventive measures to mitigate the transmission of diseases within both local and global populations. Furthermore, it is critical to implement proven conventional and contemporary strategies for managing viral infections, alongside bolstered surveillance systems. Viruses employ diverse modes of transmission, encompassing respiratory, oral-fecal, blood-borne, and vector-borne pathways. Consequently, effective measures to mitigate viral dissemination must be tailored to address each distinct route of transmission. This review discusses the existing strategies employed to mitigate the transmission and containment of viral outbreaks, as well as the dissemination of the disease within a sizable population, intending to reduce their detrimental and fatal impacts on a community.
References
J.D. Chappell, and T.S. Dermody. Biology of viruses and viral diseases. Mandell, Douglas, and Bennett's
Principles and Practice of Infectious Diseases: 1681 (2015).
ICTV. Virus Taxonomy: 2020 Release. (2022) https://talk.ictvonline.org/taxonomy/. (accessed 22 Aug 2022)
A. Wilder-Smith, and S. Osman. Public health emergencies of international concern: a historic overview. Journal
of Travel Medicine 27: taaa227 (2020).
N. Madhav, B. Oppenheim, M. Gallivan, P. Mulembakani, E. Rubin and N. Wolfe. Pandemics: risks, impacts, and
mitigation. (2018).
M. Porta. A dictionary of epidemiology. Oxford University Press (2014).
S. Drosten, S. Günther, W. Preiser, S. Van Der Werf, H.R. Brodt, and S. Becker. Identification of a novel
coronavirus in patients with severe acute respiratory syndrome. New England journal of medicine 348: 1967-1976
(2003).
A.M. Zaki, S. Van Boheemen, T.M. Bestebroer, A.D. Osterhaus, and R.A. Fouchier. Isolation of a novel
coronavirus from a man with pneumonia in Saudi Arabia. New England Journal of Medicine 367: 1814-1820
(2012).
G.J. Smith, D. Vijaykrishna, J. Bahl, S.J. Lycett, M. Worobey, and O.G. Pybus. Origins and evolutionary
genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 459: 1122-1125 (2009).
E.C. Holmes, G. Dudas, A. Rambaut and K.G. Andersen. The evolution of Ebola virus: Insights from the
–2016 epidemic. Nature 538: 193-200 (2016).
N.D. Grubaugh, N.R. Faria, K.G. Andersen, and O.G. Pybus. Genomic insights into Zika virus emergence and
spread. Cell 172: 1160-1162 (2018).
S. Riedel. Edward Jenner and the history of smallpox and vaccination. in Baylor University Medical Center
Proceedings. Taylor & Francis (2005).
I.H. Hussein, N. Chams, S. Chams, S. El Sayegh, R. Badran, and M. Raad. Vaccines through centuries: major
cornerstones of global health. Frontiers in Public Health 3: 269 (2015).
P. Bhadoria, G. Gupta, and A. Agarwal. Viral pandemics in the past two decades: an overview. Journal of family
medicine and primary care 10: 2745 (2021).
S. Roychoudhury, A. Das, P. Sengupta, S. Dutta, S. Roychoudhury, and A.P. Choudhury. Viral pandemics of the
last four decades: pathophysiology, health impacts, and perspectives. International Journal of Environmental
Research and Public Health 17: 9411 (2020).
N.D. Grubaugh, J.T. Ladner, P. Lemey, O.G. Pybus, A. Rambaut, and E.C. Holmes. Tracking virus outbreaks in
the twenty-first century. Nature Microbiology 4: 10-19 (2019).
R.M. Meganck, R.M., and R.S. Baric. Developing therapeutic approaches for twenty-first-century emerging
infectious viral diseases. Nature Medicine 27: 401-410 (2021).
N.D. Wolfe, C.P. Dunavan, and J. Diamond. Origins of major human infectious diseases. Nature 447: 279-283
(2007).
J.J. Dennehy. Evolutionary ecology of virus emergence. Annals of the New York Academy of Sciences 1389: 124-
(2017).
J.A. Blanchong, S.J. Robinson, M.D. Samuel, and J.T. Foster. Application of genetics and genomics to wildlife
epidemiology. The Journal of Wildlife Management 80: 593-608 (2016).
E.C. Holmes, A. Rambaut, and K.G. Andersen. Pandemics: spend on surveillance, not prediction. Nature
Publishing Group (2018).
W.B. Karesh, A. Dobson, J.O. Lloyd-Smith, J. Lubroth, M.A. Dixon, and M. Bennett. Ecology of zoonoses:
natural and unnatural histories. The Lancet 380: 1936-1945 (2012).
N.I. Nii‐Trebi, T.S. Mughogho, A. Abdulai, F. Tetteh, P.M. Ofosu, and M.M. Osei. Dynamics of viral disease
outbreaks: A hundred years (1918/19–2019/20) in retrospect‐Loses, lessons and emerging issues. Reviews in
Medical Virology 33: e2475 (2023).
W.J. Alonso, B.J. Laranjeira, S.A. Pereira, C.M. Florencio, E.C. Moreno, and M.A. Miller. Comparative
dynamics, morbidity and mortality burden of pediatric viral respiratory infections in an equatorial city. The
Pediatric Infectious Disease Journal 31: e9 (2012).
J.S. Kutter, M.I. Spronken, P.L. Fraaij, R.A. Fouchier, and S. Herfst. Transmission routes of respiratory viruses
among humans. Current opinion in virology 28: 142-151 (2018).
A.C. Lowen, and J. Steel. Roles of humidity and temperature in shaping influenza seasonality. Journal of
Virology 88: 7692-7695 (2014).
O. Ruuskanen, E. Lahti, L.C. Jennings, and D.R. Murdoch. Viral pneumonia. The Lancet 377: 1264-1275 (2011).
W.H. Organization. Surveillance strategies for COVID-19 human infection: interim guidance, 10 May 2020.
World Health Organization (2020)
T.M. Uyeki, J.M. Katz, and D.B. Jernigan. Novel influenza A viruses and pandemic threats. The Lancet 389:
-2174 (2017).
A.A Rabaan, S.H. Al-Ahmed, S. Haque, R. Sah, R. Tiwari, and Y.S. Malik. SARS-CoV-2, SARS-CoV, and
MERS-COV: a comparative overview. Infez Med 28: 174-184 (2020).
J.A. Al-Tawfiq, A. Zumla, P. Gautret, G.C. Gray, D.S. Hui, and A.A. Al-Rabeeah. Surveillance for emerging
respiratory viruses. The Lancet Infectious Diseases 14: 992-1000 (2014).
S.S Morse. Public health disease surveillance networks. One Health: People, Animals, and the Environment: 195-
(2014).
A.Topirceanu, M. Udrescu, and R. Marculescu. Centralized and decentralized isolation strategies and their impact
on the COVID-19 pandemic dynamics. arXiv preprint arXiv:2004.04222: (2020).
C. Wilasang, C. Sararat, N.C. Jitsuk, N. Yolai, P. Thammawijaya, and P. Auewarakul. Reduction in effective
reproduction number of COVID-19 is higher in countries employing active case detection with prompt isolation.
Journal of Travel Medicine 27: taaa095 (2020).
T. Zhao, C. Cheng, H. Liu, and C. Sun. Is one-or two-meters social distancing enough for COVID-19? Evidence
for reassessing. Public Health 185: 87 (2020).
C. Jenkins, and A. Sunjaya. Social distancing as a strategy to prevent respiratory virus infections. Respirology 26:
-144 (2021).
H. Khataee, I. Scheuring, A. Czirok, and Z. Neufeld. Effects of social distancing on the spreading of COVID-19
inferred from mobile phone data. Scientific Reports 11: 1-9 (2021).
M.E. Kretzschmar, G. Rozhnova, and M. van Boven. Isolation and contact tracing can tip the scale to containment
of COVID-19 in populations with social distancing. Frontiers in Physics 8: 677 (2021).
S. La Maestra, A. Abbondandolo, and S. De Flora. Epidemiological trends of COVID‐19 epidemic in Italy over
March 2020: From 1000 to 100 000 cases. Journal of Medical Virology 92: 1956-1961 (2020).
K. Prem, Y. Liu, T.W. Russell, A.J. Kucharski, R.M. Eggo, and N. Davies. The effect of control strategies to
reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study. The Lancet
Public Health 5: e261-e270 (2020).
A. Alborzi, M.H. Aelami, M. Ziyaeyan, M. Jamalidoust, M. Moeini, and B. Pourabbas. Viral etiology of acute
respiratory infections among Iranian Hajj pilgrims, 2006. Journal of Travel Medicine 16: 239-242 (2009).
CDC. Handwashing: Clean Hands Save Lives. (2020) https://www.cdc.gov/handwashing/index.html (accessed
Jan 2020).
G.P. Dolan, R.C. Harris, M. Clarkson, R. Sokal, G. Morgan, and M. Mukaigawara. Vaccination of health care
workers to protect patients at increased risk for acute respiratory disease. Emerging infectious diseases 18: 1225
(2012).
J. Horcajada, T. Pumarola, J. Martinez, G. Tapias, J. Bayas, and M. De la Prada. A nosocomial outbreak of
influenza during a period without influenza epidemic activity. European Respiratory Journal 21: 303-307 (2003).
R. Barranco, L. Vallega Bernucci Du Tremoul, and F. Ventura. Hospital-acquired SARS-Cov-2 infections in
patients: inevitable conditions or medical malpractice? International Journal of Environmental Research and
Public Health 18: 489 (2021).
V. Schwierzeck, J.C. König, J. Kühn, A. Mellmann, C.L. Correa-Martínez, and H. Omran. First Reported
Nosocomial Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 in a Pediatric Dialysis Unit. Clinical
Infectious Diseases 72: 265-270 (2021).
S. Plotkin. History of vaccination. Proceedings of the National Academy of Sciences 111: 12283-12287 (2014).
WHO. Types of seasonal influenza vaccine. (2020) https://www.euro.who.int/en/health-topics/communicable-
diseases/influenza/vaccination/types-of-seasonal-influenza
vaccine#:~:text=Two%20types%20of%20influenza%20vaccine,(also%20called%20trivalent%20vaccines).
(accessed 12 Nov 2020).
C.S. Ambrose, and M.J. Levin. The rationale for quadrivalent influenza vaccines. Human vaccines &
immunotherapeutics 8: 81-88 (2012).
S. Gouma, E.M. Anderson, and S.E. Hensley. Challenges of making effective influenza vaccines. Annual review
of virology 7: 495-512 (2020).
M. Shafique, M.A. Zahoor, M.I. Arshad, B. Aslam, A.B. Siddique, and M.H. Rasool. Hurdles in Vaccine
Development against Respiratory Syncytial Virus, in The Burden of Respiratory Syncytial Virus Infection in the
Young. IntechOpenpp. (2019).
S. Lee, M.T. Nguyen, M.G. Currier, J.B. Jenkins, E.A. Strobert, and A.E. Kajon. A polyvalent inactivated
rhinovirus vaccine is broadly immunogenic in rhesus macaques. Nature Communications 7: 1-7 (2016).
T. Zohar, J.C. Hsiao, N. Mehta, J. Das, A. Devadhasan, and W. Karpinski. Upper and lower respiratory tract
correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates. Cell host
& microbe: (2021).
A. Killikelly, M. Tunis, A. House, C. Quach, W. Vaudry, and D. Moore. Respiratory syncytial virus: Overview of
the respiratory syncytial virus vaccine candidate pipeline in Canada. Canada Communicable Disease Report 46:
(2020).
H. Le Calvez, M. Yu, and F. Fang. Biochemical prevention and treatment of viral infections–A new paradigm in
medicine for infectious diseases. Virology Journal 1: 12 (2004).
A. Rocca, C. Biagi, S. Scarpini, A. Dondi, S. Vandini, and L. Pierantoni. Passive Immunoprophylaxis against
Respiratory Syncytial Virus in Children: Where Are We Now? International Journal of Molecular Sciences 22:
(2021).
S. Mac, A. Sumner, S. Duchesne-Belanger, R. Stirling, M. Tunis, and B. Sander. Cost-effectiveness of
palivizumab for respiratory syncytial virus: a systematic review. Pediatrics 143: (2019).
E. Bizot, A. Bousquet, M. Charpié, F. Coquelin, S. Lefevre, and J. Le Lorier. Rhinovirus: A Narrative Review on
Its Genetic Characteristics, Pediatric Clinical Presentations, and Pathogenesis. Frontiers in Pediatrics 9: 113
(2021).
R.L. Gottlieb, A. Nirula, P. Chen, J. Boscia, B. Heller, and J. Morris. Effect of bamlanivimab as monotherapy or
in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical
trial. Jama 325: 632-644 (2021).
J.A. Englund. Antiviral therapy of influenza. in Seminars in pediatric infectious diseases. 2002. Elsevier.
CDC. Influenza vaccines — United States, 2020–21 influenza season. (2021)
https://www.cdc.gov/flu/professionals/acip/2020-2021/acip-table.htm (accessed 26 Jan 2021).
V. Gresset-Bourgeois, P.S. Leventhal, S. Pepin, R. Hollingsworth, M.P. Kazek-Duret, and I. De Bruijn.
Quadrivalent inactivated influenza vaccine (VaxigripTetra™). Expert review of vaccines 17: 1-11 (2018).
L.D. Saravolatz, K.M. Empey, R.S. Peebles Jr, and J.K. Kolls. Pharmacologic advances in the treatment and
prevention of respiratory syncytial virus. Clinical Infectious Diseases 50: 1258-1267 (2010).
J. Hendriks, and S. Blume. Measles vaccination before the measles-mumps-rubella vaccine. American journal of
public health 103: 1393-1401 (2013).
A. Bichon, C. Aubry, L. Benarous, H. Drouet, C. Zandotti, and P. Parola. Case report: Ribavirin and vitamin A in
a severe case of measles. Medicine 96: (2017).
S. Gouma, I. Hinke, T.M. Schurink-van’t Klooster, H.E. de Melker, G.J. Boland, and P. Kaaijk. Mumps-specific
cross-neutralization by MMR vaccine-induced antibodies predicts protection against mumps virus infection.
Vaccine 34: 4166-4171 (2016).
U. Sandkovsky, L. Vargas, and D.F. Florescu. Adenovirus: current epidemiology and emerging approaches to
prevention and treatment. Current infectious disease reports 16: 416 (2014).
C.H. Hoke Jr, and C.E. Snyder Jr. History of the restoration of adenovirus type 4 and type 7 vaccine, live oral
(Adenovirus Vaccine) in the context of the Department of Defense acquisition system. Vaccine 31: 1623-1632
(2013).
A. Anzueto, and M.S. Niederman. Diagnosis and treatment of rhinovirus respiratory infections. Chest 123: 1664-
(2003).
J.H. Beigel, K.M. Tomashek, L.E. Dodd, A.K. Mehta, B.S. Zingman, and A.C. Kalil. Remdesivir for the
treatment of Covid-19—preliminary report. The New England journal of medicine: (2020).
R.C. Group. Dexamethasone in hospitalized patients with Covid-19—preliminary report. New England Journal of
Medicine: (2020).
CDC. Different COVID-19 Vaccines. (2020) https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-
vaccines.html (accessed 2 Feb 2020).
T.H. Tulchinsky. John Snow, Cholera, the broad street pump; waterborne diseases then and now. Case Studies in
Public Health: 77 (2018).
R. Bonita, R. Beaglehole, and T. Kjellström, Basic epidemiology. World Health Organization (2006).
M. Kosek, C. Bern, and R.L. Guerrant. The global burden of diarrhoeal disease, as estimated from studies
published between 1992 and 2000. Bulletin of the World Health Organization 81: 197-204 (2003).
P.H. Dennehy. Effects of vaccine on rotavirus disease in the pediatric population. Current opinion in pediatrics
: 76-84 (2012).
T. Vesikari. Norovirus Vaccines in Pipeline Development, in Pediatric Vaccines and Vaccinations. Springerpp.
-292 (2021).
M.A. Widdowson, E.H. Cramer, L. Hadley, J.S. Bresee, R.S. Beard, and S.N. Bulens. Outbreaks of acute
gastroenteritis on cruise ships and on land: identification of a predominant circulating strain of norovirus—United
States, 2002. The Journal of Infectious Diseases 190: 27-36 (2004).
J. Xerry, C.I. Gallimore, M. Iturriza-Gómara, D.J. Allen, and J.J. Gray. Transmission events within outbreaks of
gastroenteritis determined through analysis of nucleotide sequences of the P2 domain of genogroup II
noroviruses. Journal of Clinical Microbiology 46: 947-953 (2008).
L. Baert, M. Uyttendaele, A. Stals, E. Van Coillie, K. Dierick, and J. Debevere. Reported foodborne outbreaks
due to noroviruses in Belgium: the link between food and patient investigations in an international context.
Epidemiology & Infection 137: 316-325 (2009).
G. Belliot, A. Lavaux, D. Souihel, D. Agnello, and P. Pothier. Use of murine norovirus as a surrogate to evaluate
resistance of human norovirus to disinfectants. Applied and environmental microbiology 74: 3315-3318 (2008).
I. Barrabeig, A. Rovira, J. Buesa, R. Bartolomé, R. Pintó, H. Prellezo, and À. Domínguez. Foodborne norovirus
outbreak: the role of an asymptomatic food handler. BMC Infectious Diseases 10: 1-7 (2010).
M. Romão, A. Didier, and A. Brandes. www. cdc. gov/eid. Emerging Infectious Diseases: 1310 (2011).
M. O’Ryan, Y. Lucero, and A.C. Linhares. Rotarix®: vaccine performance 6 years postlicensure. Expert review
of vaccines 10: 1645-1659 (2011).
S. La Frazia, A. Ciucci, F. Arnoldi, M. Coira, P. Gianferretti, and M. Angelini. Thiazolides, a new class of
antiviral agents effective against rotavirus infection, target viral morphogenesis, inhibiting viroplasm formation.
Journal of Virology 87: 11096-11106 (2013).
J.M. Hyser, and M.K. Estes. Rotavirus vaccines and pathogenesis: 2008. Current Opinion in Gastroenterology
: 36 (2009).
J. Kocher, and L. Yuan. Norovirus vaccines and potential antinorovirus drugs: recent advances and future
perspectives. Future Virology 10: 899-913 (2015).
C. Bravo, L. Mege, C. Vigne, and Y. Thollot. Clinical experience with the inactivated hepatitis A vaccine,
Avaxim 80U Pediatric. Expert Review of Vaccines 18: 209-223 (2019).
K. Van Herck, G. Leroux-Roels, P. Van Damme, K. Srinivasa, and B. Hoet. Ten-year antibody persistence
induced by hepatitis A and B vaccine (Twinrix™) in adults. Travel medicine and infectious disease 5: 171-175
(2007).
E. Ehrenfeld, J. Modlin, and K. Chumakov. Future of polio vaccines. Expert review of vaccines 8: 899-905
(2009).
L. Prescott, J. Harley, and D. Klein. Microbiology. 5th. McGraw Hil1: (2002).
F. Gobbi, L. Barzon, G. Capelli, A. Angheben, M. Pacenti, and G. Napoletano. Surveillance for West Nile,
dengue, and chikungunya virus infections, Veneto Region, Italy, 2010. Emerging Infectious Diseases 18: 671
(2012).
B. Dietzschold, J. Li, M. Faber, and M. Schnell. Concepts in the pathogenesis of rabies. (2008).
O. Ergönül. Crimean-Congo haemorrhagic fever. The Lancet Infectious Diseases 6: 203-214 (2006).
V. Sikka, V.K. Chattu, R.K. Popli, S.C. Galwankar, D. Kelkar, and S.G. Sawicki. The emergence of Zika virus as
a global health security threat: a review and a consensus statement of the INDUSEM Joint Working Group
(JWG). Journal of Global Infectious Diseases 8: 3 (2016).
WHO. How to Avoid vector-Borne diseases – top tips. (2014) https://www.who.int/westernpacific/about/how-we-
work/pacific-support/news/detail/07-04-2014-world-health-day-2014-preventing-vector-borne-diseases (accessed
Nov 2020).
H. van den Berg, M. Zaim, R.S. Yadav, A. Soares, B. Ameneshewa, A. Mnzava, J. Hii, A.P. Dash, and M. Ejov.
Global trends in the use of insecticides to control vector-borne diseases. Environmental Health Perspectives 120:
-582 (2012).
S.D. Rodriguez, H.-N. Chung, K.K. Gonzales, J. Vulcan, Y. Li, and J.A. Ahumada. Efficacy of some wearable
devices compared with spray-on insect repellents for the yellow fever mosquito, Aedes aegypti (L.)(Diptera:
Culicidae). Journal of Insect Science 17: 24 (2017).
I. Unlu, D.S. Suman, Y. Wang, K. Klingler, A. Faraji, and R. Gaugler. Effectiveness of autodissemination stations
containing pyriproxyfen in reducing immature Aedes albopictus populations. Parasites & vectors 10: 1-10 (2017).
S.A. Ritchie, G.J. Devine, G.M. Vazquez-Prokopec, A.E. Lenhart, P. Manrique-Saide, and T.W. Scott,
Insecticide-based approaches for dengue vector control, in Ecology and Control of Vector-Borne Diseases.
Wageningen Academic Publisherspp. 380-390 (2021).
Z.H. Amelia-Yap, C.D. Chen, M. Sofian-Azirun, and V.L. Low. Pyrethroid resistance in the dengue vector Aedes
aegypti in Southeast Asia: present situation and prospects for management. Parasites & Vectors 11: 1-17 (2018).
N.L. Achee, M.J. Bangs, R. Farlow, G.F. Killeen, S. Lindsay, J.G. Logan, S.J. Moore, M. Rowland, K. Sweeney,
S.J. Torr, and L.J. Zwiebel. Spatial repellents: from discovery and development to evidence-based validation.
Malaria Journal 11: 1-9 (2012).
N.L. Achee, J.P. Grieco, H. Vatandoost, G. Seixas, J. Pinto, and L. Ching-Ng. Alternative strategies for mosquito-
borne arbovirus control. PLoS Neglected Tropical Diseases 13: e0006822 (2019).
T. Glare, and M. O’Callaghan. Bacillus thuringiensis: Biology, Ecology and Safety. John Wiley & Sons. Inc.,
New York, NY: (2000).
X. Zheng, D. Zhang, Y. Li, C. Yang, Y. Wu, and X. Liang. Incompatible and sterile insect techniques combined
eliminate mosquitoes. Nature 572: 56-61 (2019).
R.S. Lees, J.R. Gilles, J. Hendrichs, M.J. Vreysen, and K. Bourtzis. Back to the future: the sterile insect technique
against mosquito disease vectors. Current Opinion in Insect Science 10: 156-162 (2015).
B. Durovni, V. Saraceni, A. Eppinghaus, T.I. Riback, L.A. Moreira, and N.P. Jewell. The impact of large-scale
deployment of Wolbachia mosquitoes on dengue and other Aedes-borne diseases in Rio de Janeiro and Niterói,
Brazil: study protocol for a controlled interrupted time series analysis using routine disease surveillance data.
F1000Research 8: (2019).
S.B. Pinto, T.I. Riback, G. Sylvestre, G. Costa, J. Peixoto, and F.B. Dias. Effectiveness of Wolbachia-infected
mosquito deployments in reducing the incidence of dengue and other Aedes-borne diseases in Niterói, Brazil: A
quasi-experimental study. PLoS Neglected Tropical Diseases 15: e0009556 (2021).
S. Haq, R. Yadav, and V. Kohli. Developing larvivorous fish network for mosquito control in urban areas: A case
study. ICMR Bull 33: 69-73 (2003).
R. Bellini, H. Zeller, and W. Van Bortel. A review of the vector management methods to prevent and control
outbreaks of West Nile virus infection and the challenge for Europe. Parasites & Vectors 7: 1-11 (2014).
J.M. Darbro, and M.B. Thomas. Spore persistence and likelihood of aeroallergenicity of entomopathogenic fungi
used for mosquito control. The American Journal of Tropical Medicine and Hygiene 80: 992-997 (2009).
S. Flasche, M. Jit, I. Rodríguez-Barraquer, L. Coudeville, M. Recker, and K. Koelle. The long-term safety, public
health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine
(Dengvaxia): a model comparison study. PLoS Medicine 13: e1002181 (2016).
T.D. Querec, R.S. Akondy, E.K. Lee, W. Cao, H.I. Nakaya, and D. Teuwen. Systems biology approach predicts
immunogenicity of the yellow fever vaccine in humans. Nature Immunology 10: 116-125 (2009).
R. Ghildiyal, and R. Gabrani. Antiviral therapeutics for chikungunya virus. Expert Opinion on Therapeutic
Patents 30: 467-480 (2020).
A.C. Sayce, J.L. Miller, and N. Zitzmann. Glucocorticosteroids as dengue therapeutics: resolving clinical
observations with a primary human macrophage model. Clinical Infectious Diseases 56: 901-903 (2013).
Y.S. Tian, Y. Zhou, T. Takagi, M. Kameoka, and N. Kawashita. Dengue virus and its inhibitors: a brief review.
Chemical and Pharmaceutical Bulletin 66: 191-206 (2018).
E. Escribano-Romero, N.J. de Oya, E. Domingo, and J.C. Saiz. Extinction of West Nile virus by favipiravir
through lethal mutagenesis. Antimicrobial agents and chemotherapy 61: (2017).
J. Arroyo, C. Miller, J. Catalan, G.A. Myers, M.S. Ratterree, D.W. Trent, et al. ChimeriVax-West Nile virus live-
attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. Journal of virology 78: 12497-
(2004).
T.P. Monath. Treatment of yellow fever. Antiviral research 78: 116-124 (2008).
S.C. Weaver, J.E. Osorio, J.A. Livengood, R. Chen, and D.T. Stinchcomb. Chikungunya virus and prospects for a
vaccine. Expert review of vaccines 11: 1087-1101 (2012).
T.W. Geisbert, C.E. Mire, J.B. Geisbert, Y.P. Chan, K.N. Agans, and F. Feldmann. Therapeutic treatment of
Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody. Science
translational medicine 6: 242ra82-242ra82 (2014).
WHO. HIV/AIDS. (2020) https://www.who.int/news-room/fact-sheets/detail/hiv-aids (accessed 12 Nov 2020).
WHO. Hepatitis B. (2020) https://www.who.int/news-room/fact-sheets/detail/hepatitis-
b#:~:text=Hepatitis%20B%20is%20a%20potentially,from%20cirrhosis%20and%20liver%20cancer. (accessed 12
Nov 2020).
WHO. Hepatitis C. (2021) https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (accessed 30 Sep 2021).
R.M. Benjamin. Raising awareness of viral hepatitis: National Hepatitis Testing Day, May 19. Public Health
Reports 127: 244-245 (2012).
R.C. Burke, K.A. Sepkowitz, K.T. Bernstein, A.M. Karpati, J.E. Myers, and B.W. Tsoi. Why don't physicians test
for HIV? A review of the US literature. Aids 21: 1617-1624 (2007).
B.D. Smith, C. Jorgensen, J.E. Zibbell, and G.A. Beckett. Centers for Disease Control and Prevention initiatives
to prevent hepatitis C virus infection: a selective update. Clinical Infectious Diseases 55: S49-S53 (2012).
WHO. Screening donated blood for transfusion-transmissible infections: recommendations. World Health
Organization (2010).
E. Sagnelli, G. Starnini, C. Sagnelli, R. Monarca, G. Zumbo, E. Pontali. Blood born viral infections, sexually
transmitted diseases and latent tuberculosis in Italian prisons: a preliminary report of a large multicenter study.
Eur Rev Med Pharmacol Sci 16: 2142-6 (2012).
L.A. Scott-Sheldon, T.B. Huedo-Medina, M.R. Warren, B.T. Johnson, and M.P. Carey. Efficacy of behavioral
interventions to increase condom use and reduce sexually transmitted infections: a meta-analysis, 1991 to 2010.
Journal of Acquired Immune Deficiency Syndromes (1999) 58: 489 (2011).
J. Obiero, P.G. Mwethera, G.D. Hussey, and C.S. Wiysonge. Vaginal microbicides for reducing the risk of sexual
acquisition of HIV infection in women: systematic review and meta-analysis. BMC Infectious Diseases 12: 289
(2012).
N. Siegfried, M. Muller, J.J. Deeks, and J. Volmink. Male circumcision for prevention of heterosexual acquisition
of HIV in men. Cochrane Database of Systematic Reviews: (2009).
H. Hagan, and D.C.D. Jarlais. HIV and HCV infection among injecting drug users. Mount Sinai Journal of
Medicine 67: 423-428 (2000).
CDC. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2017 Update
https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf (12 Nov 2020).
CDC. Guidelines and Recommendations. (2020) https://www.cdc.gov/hiv/guidelines/index.html (accessed 12
Nov 2020).
K.H. Mayer, and K.K. Venkatesh. Antiretroviral therapy as HIV prevention: status and prospects. American
journal of public health 100: 1867-1876 (2010).
M.L. Cottrell, K.H. Yang, H.M. Prince, C. Sykes, N. White, and S. Malone. A translational pharmacology
approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir
disoproxil fumarate with or without emtricitabine. The Journal of Infectious Diseases 214: 55-64 (2016).
A.S. Omrani, and A. Freedman. Prophylaxis of HIV infection. British Medical Bulletin 73: 93-105 (2005).
D. Gold, and L. Corey. Acyclovir prophylaxis for herpes simplex virus infection. Antimicrobial agents and
chemotherapy 31: 361-367 (1987).
K. Kawamura, H. Wada, R. Yamasaki, Y. Ishihara, K. Sakamoto, and M. Ashizawa. Low‐dose acyclovir
prophylaxis for the prevention of herpes simplex virus disease after allogeneic hematopoietic stem cell
transplantation. Transplant Infectious Disease 15: 457-465 (2013).
H.S. Khurana, A. Kole, J. Falk, S. Ghandehari, G. Soohoo, and S. Simsir. Low-Dose Valganciclovir for CMV
Prophylaxis after Lung Transplantation. International Scholarly Research Notices 2013: (2013).
J.K. McGavin, and K.L. Goa. Ganciclovir. Drugs 61: 1153-1183 (2001).
H. Bayu, B. Elias, S. Abdisa, A. Tune, and H. Namo. Post exposure prophylaxis coverage, vertical transmission
and associated factors among hepatitis B exposed newborns delivered at Arsi zone health institutions, 2019. Plos
one 15: e0238987 (2020).
S. Paladini, P. Van Damme, and A.R. Zanetti. The worldwide impact of vaccination on the control and protection
of viral hepatitis B. Digestive and Liver Disease 43: S2-S7 (2011).
W.E. Levinson. Review of medical microbiology and immunology. McGraw Hill Professional (2020).
L. Piermatteo, S. D’Anna, A. Bertoli, M. Bellocchi, L. Carioti, and L. Fabeni. Unexpected rise in the circulation
of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on
HBsAg detection/quantification and vaccination strategies. Emerging Microbes & Infections 12: 2219347 (2023).
J. Leong, D. Lin, and M.H. Nguyen. Hepatitis B surface antigen escape mutations: Indications for initiation of
antiviral therapy revisited. World journal of clinical cases 4: 71 (2016).
J. Liu, A. Kosinska, M. Lu, and M. Roggendorf. New therapeutic vaccination strategies for the treatment of
chronic hepatitis B. Virologica Sinica 29: 10-16 (2014).
A. Washizaki, A. Murayama, M. Murata, T. Kiyohara, K. Yato, and N. Yamada. Neutralization of hepatitis B
virus with vaccine-escape mutations by hepatitis B vaccine with large-HBs antigen. Nature Communications 13:
(2022).
Y.H. Shin, C.M. Park, and C.H. Yoon. An Overview of Human Immunodeficiency Virus-1 Antiretroviral Drugs:
General Principles and Current Status. Infection & Chemotherapy 53: 29 (2021).
A. Winston, A.G. Wurcel, C. Gordon, and N. Goyal. Viral hepatitis in patients on hemodialysis. In Seminars in
dialysis. 2020. Wiley Online Library.
R. Zampino, C. Sagnelli, A. Boemio, E. Sagnelli, and N. Coppola. Treatment of chronic HBV infection in
developing countries. Annals of Hepatology 15: 816-823 (2017).
X.J. Qian, Y.Z. Zhu, P. Zhao, and Z.T. Qi. Entry inhibitors: new advances in HCV treatment. Emerging Microbes
& Infections 5: 1-8 (2016).
A.d.A. Monforte, A.C. Lepri, G. Rezza, P. Pezzotti, A. Antinori, and A.N. Phillips. Insights into the reasons for
discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral
naive patients. Aids 14: 499-507 (2000).
E.D. Belay, J.C. Kile, A.J. Hall, C. Barton-Behravesh, M.B. Parsons, and S. Salyer. Zoonotic disease programs
for enhancing global health security. Emerging infectious diseases 23: S65 (2017).
P. Olliaro, F. Fouque, A. Kroeger, L. Bowman, R. Velayudhan, A.C. Santelli, D. Garcia, R. Skewes Ramm, L.H.
Sulaiman, G.S. Tejeda, and F.C. Morales. Improved tools and strategies for the prevention and control of
arboviral diseases: A research-to-policy forum. PLoS Neglected Tropical Diseases 12: e0005967 (2018).
C.R. Parrish, E.C. Holmes, D.M. Morens, E.C. Park, D.S. Burke, and C.H. Calisher. Cross-species virus
transmission and the emergence of new epidemic diseases. Microbiology and Molecular Biology Reviews 72:
-470 (2008).
M. Rahman, M. Sobur, M. Islam, S. Ievy, M. Hossain, and M.E. El Zowalaty. Zoonotic diseases: etiology,
impact, and control. Microorganisms 8: 1405 (2020).
S. Alrashed, N. Min-Allah, I. Ali, and R. Mehmood. COVID-19 outbreak and the role of digital twin. Multimedia
Tools and Applications 81: 26857-26871 (2022).
A. Vallée. Digital twin for healthcare systems. Frontiers in Digital Health 5: 1253050 (2023).
M.N. Kamel Boulos, and P. Zhang. Digital twins: from personalised medicine to precision public health. Journal
of Personalized Medicine 11: 745 (2021).
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Upon acceptance of an article, its copyright will be assigned to the Pakistan Academy of Sciences.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY). Allows users to: copy the article and distribute; abstracts, create extracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation); include in a collective work (such as an anthology); and text or data mine the article. These uses are permitted even for commercial purposes, provided the user: includes a link to the license; indicates if changes were made; gives appropriate credit to the author(s) (with a link to the formal publication through the relevant DOI); and does not represent the author(s) as endorsing the adaptation of the article or modify the article in such a way as to damage the authors' honor or reputation.
